4 stories this morning, for surgeons and the people who support them.
- Centinel Spine files publicly for a NYSE IPO under CNTL: first-half 2026 revenue $85.2M (+42%), net income $10.2M, pure-play prodisc total disc replacement — Centinel Spine Holdco, Inc. (West Chester, PA) filed Form S-1 with the SEC on Oct 7, 2026 (accession 0001104659-26-114375; earlier confidential DRS May 8, 2026, DRS/A Jun 29 and Aug 3). Verified against the S-1 text: intends to list Class A common on the NYSE as 'CNTL'; Up-C structure; price range blank; bookrunners Morgan Stanley, Goldman Sachs & Co., Piper Sandler, Canaccord Genuity, BTIG. Six months ended Jun 30, 2026: total revenue $85,244K vs $60,058K (+42%); U.S. $72,879K vs $49,542K (+47%), driven by a 56% rise in U.S. unit volume; gross margin 82% vs 80%; net income $10.2M vs net loss $0.5M; adjusted EBITDA $15.5M. FY2025 revenue $132.2M (+39%), net loss $4.3M. 1,736 U.S. surgeons performed at least one prodisc TDR in the four quarters to Jun 30, 2026 (+33%), of more than 3,100 U.S. surgeons who performed any TDR in the last two years. Portfolio: four cervical TDR systems and one lumbar; the S-1 claims pro disc is the only TDR platform with FDA-approved multi-level indications in both cervical and lumbar spine (company claim, attributed as such in the script). The S-1 cites a MAUDE analysis (Jan 2005-Sep 2025 window per filing) of osteolysis reports: 138 M6, 16 Simplify, 2 Mobi-C, 2 Prestige, 1 Prodisc-C (attributed in the script as the filing's citation). Proceeds: offering expenses, repay the 2023 Credit Agreement, pay down the Feb 25, 2025 SLR Investment Corp. loan ($60.0M borrowed) and 2025 Credit Agreement, sales/marketing, R&D/clinical trials, capex. Q3 2026 preliminary ranges are left blank in this filing. Second sources: Renaissance Capital, Oct 7, 2026 (https://www.renaissancecapital.com/IPO-Center/News/122099/spinal-implant-developer-centinel-spine-files-for-a-100-million-ipo) - up to $100M placeholder raise, no pricing terms; Reuters via Investing.com (https://www.investing.com/news/economy-news/medical-device-maker-centinel-spine-discloses-revenue-rise-in-us-ipo-filing-4937575). Prior coverage: Centinel appeared only as a growth figure (+34.4% in 2025) inside the 2026-09-22 ORTHOWORLD spine-market story; the IPO filing has not been covered (grep of all drafts). Source
- MRI2CT announces FDA 510(k) clearance for NextMR Spine, cloud software that generates 3D lumbar spine and sacrum bone images from standard MRI, entering a category MRIguidance's BoneMRI has held since 2022 — FDA 510(k) database: K260525, NextMR Spine, MRI2CT, Inc. (Claymont, DE), received Feb 17, 2026, decision Sep 4, 2026, substantially equivalent, product code QIH, 21 CFR 892.2050, traditional review. Company announced the clearance Oct 7, 2026 via Business Wire (https://www.financialcontent.com/article/bizwire-2026-10-7-mri2ct-receives-fda-510k-clearance-for-nextmr-enabling-3d-bone-visualization-from-standard-spine-mri): 3D bone visualization of the lumbar spine and sacrum from routine 1.5T and 3T MRI sequences, output in under 60 seconds, cloud-based, multiplanar plus 3D via web or DICOM; validated on a retrospective set of 145 adults with paired MRI and CT from U.S. and Israeli sites with submillimeter cortical delineation (company-reported); the release states NextMR images are 'not intended to replace CT images in general' and users must verify compatibility with third-party devices. Second source: AuntMinnie, Oct 7, 2026 (https://www.auntminnie.com/clinical-news/mri/news/15836912/mri2ct-gets-fda-clearance-for-mribased-spine-imaging-software). Competitive context: MRIguidance BoneMRI cleared for the pelvis Jan 2022 and extended to the lumbar spine with v1.4 on Nov 16, 2022 (K221762), with later clearances covering cervical, thoracic, lumbar and S1 levels (AuntMinnie, https://www.auntminnie.com/imaging-informatics/advanced-visualization/image-processing/article/15630206/mriguidance-secures-fda-clearance-for-bonemri). No prior coverage of MRI2CT, NextMR, BoneMRI or synthetic CT in any draft (grep). Source
- Smith+Nephew launches CARTIHEAL AGILI-C in 12 European markets ahead of the ICRS Summit in Porto, on five-year RCT data against microfracture and debridement — Smith+Nephew release, Oct 6, 2026: CARTIHEAL AGILI-C aragonite-based biphasic scaffold for knee chondral and osteochondral lesions launches initially in Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Switzerland and the UK, with more countries to follow; introduced commercially in the U.S. in 2024; featured at the ICRS Summit, Porto, Oct 8-10, 2026. Release does not state the regulatory basis or price. Trial data verified via NCBI E-utilities: Altschuler N et al., Am J Sports Med 2026 May;54(6):1376-1385 (PMID 41992573), five-year follow-up of the pivotal RCT: 26 centers, 8 countries, 2:1 randomization, 167 implant vs 84 surgical standard of care (arthroscopic debridement or microfracture), Kellgren-Lawrence 0-3 allowed. Overall KOOS at final follow-up 81.0 vs 59.1 (22.6-point difference, 95% CI 16.6-28.7); responder rate 74.7% vs 29.6%; treatment failure 15.0% vs 35.7% (P<.001); mild-to-moderate OA subgroup failure 13.2% vs 40.7%. First author was affiliated with CartiHeal Ltd on the 2023 two-year report (AJSM 2023;51(4):957-967). Second source: Orthopedics This Week listing Oct 7, 2026 (https://orthotw.com/). Prior coverage: AGILI-C appeared only as competitive context in the 2026-09-04 draft (FDA approval 2022, Category I CPT code); the European launch has not been covered (grep). Source
- KSSTA, Bridge registry two-year results for Miach's BEAR implant: 5.6% ipsilateral ACL retear, none in year one, but 18.9% overall reoperation (28.0% original vs 7.5% modified technique) — Wittstein J, Strickland S, Gomoll A, Sherman S, Lau B, Taylor D, Kramer D, Keyes S, Meininger AK, Pietropaoli M, McMillan S, Brady J. Knee Surg Sports Traumatol Arthrosc, online Sep 30, 2026, doi 10.1002/ksa.70606, PMID 42814471; verified against the abstract via NCBI E-utilities. First 100 patients of the post-commercialization Bridge registry; mean follow-up 22.3 months; mean age 31.8; 67% female; 55 original technique, 45 modified. Ipsilateral ACL retear 5.6% (5/90), all five between 14 and 28 months; overall reoperation 18.9% (17/90) at 2 years, 28.0% original vs 7.5% modified technique (p=0.02); no significant difference in retear between techniques; events include meniscal injuries, two manipulations under anesthesia, one cyclops/lysis of adhesions, four retained-suture removals, two contralateral tears. Miach release Oct 7, 2026 via Business Wire (repost https://orthospinenews.com/2026/10/07/new-real-world-data-for-miach-orthopaedics-bear-implant-demonstrate-low-retear-rates-and-clinically-meaningful-improvements-following-acl-restoration/): mean IKDC 87.4, KOOS Pain 94.7, KOOS Sport/Rec 88.2, return to sport 87.2% at two years; retear 2.5% modified vs 8.0% original; more than 10,000 U.S. patients treated since launch. The one-year report from the same registry (KSSTA, PMID 40801127) disclosed that all authors received funding or sponsorship from Miach. No prior Morning Brief coverage of Miach or the BEAR implant (grep for Miach; 'BEAR' hits are only 'weight-bearing'). Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.